Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Update on hepatitis G virus].

C Déjean1, P Berthoux, S Cecillon

  • 1Interne en Pharmacie Hospitalière, Pharmacie centrale, CHU Dupuytren, Limoges.

Presse Medicale (Paris, France : 1983)
|October 16, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Ethical stakes of information in radiation oncology: Thinking the risk and building the therapeutic alliance].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2023
Same author

[Crisis situations: Ethical reflection on prioritization of care access in radiation oncology].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2022
Same author

The inverse square law: A basic principle in brachytherapy.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2022
Same author

Radiotherapy and pregnancy.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2021
Same author

Radiotherapy for penile cancers.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2021
Same author

A priori quality assurance using a benchmark case of the randomized phase 2 GORTEC 2014-14 in oligometastatic head and neck cancer patients.

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2021
Same journal

Predictive analytics and risk stratification models in internal medicine: from risk scores to real-time machine learning.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in skin disease therapeutics: from drug discovery to personalized treatment pathways.

Presse medicale (Paris, France : 1983)·2026
Same journal

AI in clinical diagnostics in dermatology: applications, validation, and real-world use cases.

Presse medicale (Paris, France : 1983)·2026
Same journal

Artificial Intelligence in medical research and publishing: progress, risks, and future perspectives.

Presse medicale (Paris, France : 1983)·2026
Same journal

Ethical, legal, and regulatory challenges in AI-based healthcare tools.

Presse medicale (Paris, France : 1983)·2026
Same journal

Decision-making for clinicians.

Presse medicale (Paris, France : 1983)·2026
See all related articles

Hepatitis G virus (HGV) shows low pathogenicity, with no chronic hepatitis observed. Coinfections with HCV and HIV do not worsen outcomes, and anti-E2 antibodies indicate HGV elimination.

Area of Science:

  • Virology
  • Hepatology

Context:

  • Hepatitis G virus (HGV) shares genomic similarities with Hepatitis C virus (HCV).
  • The pathogenic power of HGV requires further elucidation.
  • HGV infections are prevalent in transplant recipients.

Purpose:

  • To describe the characteristics and clinical significance of Hepatitis G virus.
  • To investigate the impact of HGV coinfections on patient prognosis.
  • To assess the prevalence of HGV in specific patient populations.

Summary:

  • Hepatitis G virus is an RNA virus with genomic similarities to HCV.
  • No cases of chronic hepatitis have been linked to HGV.
  • Coinfections with HCV and HIV do not alter the prognosis.
  • Anti-E2 antibodies in serum correlate with HGV genome elimination and neutralization.

Related Experiment Videos

  • A high prevalence (31%) of HGV is observed in transplant recipients, without reported impact on graft function.

    • Impact:

    • Understanding HGV's low pathogenicity is crucial for differentiating it from other hepatitis viruses.
    • Identifying anti-E2 antibodies as a marker for HGV clearance aids in assessing infection outcomes.
    • The high prevalence in transplant recipients highlights the need for monitoring HGV in immunocompromised individuals.